McKesson Co. (NYSE:MCK) Shares Sold by Private Wealth Partners LLC

Private Wealth Partners LLC decreased its holdings in McKesson Co. (NYSE:MCK) by 0.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 51,979 shares of the company’s stock after selling 141 shares during the period. McKesson comprises approximately 2.0% of Private Wealth Partners LLC’s portfolio, making the stock its 18th largest position. Private Wealth Partners LLC’s holdings in McKesson were worth $24,065,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Addison Advisors LLC grew its stake in shares of McKesson by 7.9% during the fourth quarter. Addison Advisors LLC now owns 299 shares of the company’s stock worth $138,000 after purchasing an additional 22 shares in the last quarter. Citizens Financial Group Inc. RI grew its stake in shares of McKesson by 26.0% during the fourth quarter. Citizens Financial Group Inc. RI now owns 950 shares of the company’s stock worth $440,000 after purchasing an additional 196 shares in the last quarter. Kovack Advisors Inc. grew its stake in shares of McKesson by 96.1% during the fourth quarter. Kovack Advisors Inc. now owns 1,508 shares of the company’s stock worth $698,000 after purchasing an additional 739 shares in the last quarter. Bryn Mawr Capital Management LLC grew its stake in shares of McKesson by 140.7% during the fourth quarter. Bryn Mawr Capital Management LLC now owns 2,313 shares of the company’s stock worth $1,071,000 after purchasing an additional 1,352 shares in the last quarter. Finally, McClarren Financial Advisors Inc. acquired a new position in shares of McKesson during the fourth quarter worth $172,000. Institutional investors and hedge funds own 85.07% of the company’s stock.

Insider Activity at McKesson

In related news, EVP Leann B. Smith sold 186 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $496.00, for a total value of $92,256.00. Following the completion of the sale, the executive vice president now owns 1,511 shares in the company, valued at $749,456. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, EVP Leann B. Smith sold 186 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $496.00, for a total value of $92,256.00. Following the completion of the sale, the executive vice president now owns 1,511 shares in the company, valued at $749,456. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Brian S. Tyler sold 3,473 shares of the firm’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $524.55, for a total transaction of $1,821,762.15. Following the completion of the sale, the chief executive officer now owns 43,445 shares of the company’s stock, valued at approximately $22,789,074.75. The disclosure for this sale can be found here. 0.21% of the stock is owned by insiders.

McKesson Price Performance

Shares of NYSE:MCK traded up $3.36 on Friday, reaching $543.30. The company’s stock had a trading volume of 654,669 shares, compared to its average volume of 493,786. The stock’s 50-day moving average is $528.15 and its two-hundred day moving average is $489.72. McKesson Co. has a 52-week low of $352.34 and a 52-week high of $544.81. The stock has a market capitalization of $71.40 billion, a P/E ratio of 24.62, a PEG ratio of 1.44 and a beta of 0.45.

McKesson (NYSE:MCK) last announced its earnings results on Wednesday, February 7th. The company reported $7.74 EPS for the quarter, beating analysts’ consensus estimates of $7.05 by $0.69. The business had revenue of $80.90 billion during the quarter, compared to analysts’ expectations of $77.93 billion. McKesson had a net margin of 0.99% and a negative return on equity of 262.63%. The business’s revenue was up 14.8% compared to the same quarter last year. During the same period in the prior year, the company earned $6.90 earnings per share. Equities analysts forecast that McKesson Co. will post 27.59 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, July 1st. Investors of record on Monday, June 3rd will be given a $0.62 dividend. The ex-dividend date is Friday, May 31st. This represents a $2.48 dividend on an annualized basis and a yield of 0.46%. McKesson’s payout ratio is currently 11.24%.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on MCK shares. Mizuho boosted their target price on shares of McKesson from $450.00 to $505.00 and gave the stock a “neutral” rating in a research note on Friday, February 9th. Morgan Stanley upped their price objective on shares of McKesson from $522.00 to $548.00 and gave the company an “overweight” rating in a research note on Monday, April 15th. Barclays started coverage on shares of McKesson in a research note on Wednesday, January 3rd. They issued an “overweight” rating and a $537.00 price objective for the company. StockNews.com upgraded shares of McKesson from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Finally, Argus upped their price objective on shares of McKesson from $510.00 to $570.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Two equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, McKesson presently has an average rating of “Moderate Buy” and a consensus price target of $533.50.

McKesson Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.